

SGARD P

GARDP'S NON-PROFIT APPROACH TO ANTIBIOTIC R&D AND ACCESS:

FOCUS ON LATIN AMERICA AND THE CARIBBEAN

Antimicrobial resistance (AMR) poses a public health threat that is on the rise, with Latin America and the Caribbean predicted to have one of the highest AMR mortality rates by 2050.¹ Over the past decade, the global community has made progress on this issue by improving antibiotic stewardship and expanding infection prevention and control measures. But because bacteria by nature evolve to survive, effective new antibiotics that are accessible in regions hardest hit by AMR are still desperately needed both now and in the future.

The Global Antibiotic Research & Development Partnership (GARDP) was legally established in 2018 to respond to this need.² GARDP works in partnership to develop new antibiotic treatments that target the World Health Organization's bacterial priority pathogens—the causes of multidrug-resistant infections that pose the greatest threat to public health—and improve access to essential antibiotics. These two interventions are expected to have a dramatic effect on countering the rise and spread of AMR. Improving access alone could prevent more than 50 million deaths by 2050.¹

As a not-for-profit organization with staff in Brazil and other strategic locations, GARDP works on interventions that aim to have a public health impact, in particular antibiotic development and access for high-burden countries and key populations including children and neonates. GARDP forges collaboration and license agreements to derisk antibiotic development and contribute to the manufacturing process. Through these agreements, GARDP obtains product commercialization rights for countries that are hit hard by AMR but typically neglected in the rollout of new antibiotic products. Greater patient numbers and higher corresponding product volumes in these countries mean that GARDP is able to address the public health need while contributing to a sustainable market with stable supply.

Bacteria continue to evolve and so must the global AMR response. GARDP stands ready to strengthen antibiotic innovation and access through partnerships in Latin America and the Caribbean.

AMR in Latin America and the Caribbean¹

- **322,000:** The number of deaths in 2021 alone in which AMR played a role
- 13+ million: The forecasted number of deaths in which AMR will play a role, 2025-2050
- 22.1/100,000: The forecasted death rate attributable to AMR by 2050, one of the highest globally





"With the AMR crisis reaching a tipping point, GARDP's unique antibiotic innovation and access model is as important now as ever in Latin America and beyond."

Dr José Gomes Temporão

Former Brazil Health Minister and current GARDP Board member

- 1. Naghavi, Mohsen et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet (2024)
- 2. GARDP was legally established in Switzerland as the GARDP Foundation.

Bridging antibiotic R&D and access: GARDP's programmatic areas and portfolio

GARDP has built a portfolio of potential and approved treatments across key disease areas—serious bacterial infections and sepsis in adults, children and neonates, as well as sexually transmitted infections—that span the antibiotic pipeline from antibiotic discovery to post-registration studies and access. GARDP has also created a first-rate online platform for the antimicrobial R&D community, known as REVIVE. Along with its broader policy, advocacy and access initiatives like SECURE, GARDP is contributing to a new antibiotic R&D ecosystem that serves global public health needs.

SERIOUS BACTERIAL INFECTIONS & SEPSIS

- Cefiderocol (developed by Shionogi)¹
- BWC 0977 (in co-development with Bugworks)¹

NEONATAL SEPSIS

• Three potential new empiric treatment regimens with generic antibiotics: 1) fosfomycin-amikacin; 2) fosfomycinflomoxef; 3) flomoxef-amikacin

SEXUALLY TRANSMITTED INFECTIONS

 Zoliflodacin (co-developed with Innoviva Specialty Therapeutics)²

DISCOVERY & EXPLORATORY RESEARCH

Collaborative research to identify and optimize antibiotics for preclinical development

CONNECTING THE R&D COMMUNITY



 An antimicrobial R&D community and online platform, including researchers in Latin America and the Caribbean

- GARDP's commercialization rights include all of Latin America and the Caribbean (LAC).
- 2. GARDP's commercialization rights include all of LAC, with the exception of Argentina and Mexico.

Advancing action on AMR in Latin America and the Caribbean

Sep. 2022

PAHO initiates study on surveillance for drug susceptibility in CR organisms

June 2023

GARDP and partners publish findings from global observational study on neonatal sepsis, which included Santa Casa de São Paulo School of Medical Sciences and HC de Ribeirão Preto

lune 2024

GARDP and PAHO co-host event at Brazil G20 Health Working Group

June 2024

GARDP starts discussions with potential sites Unifesp, UFRJ, Cemetron on generating cefiderocol use evidence in Brazil

Sep. 2024

GARDP and PAHO sign master framework agreement

Jan. 2025

Fiocruz and Aries/Unifesp serve as collaborating organizations for GARDP and BSAC's ACC2025

Mar. 2025

Dr José Gomes Temporão, former Brazilian Health Minister, joins GARDP Board

Apr. 2025

Fiocruz supports the implementation of a Brazil cefiderocol research agenda through its units VPPCB Clinical Research Platform and LabSUR

May 2025

GARDP launches Rfl to identify cefiderocol commercial partner to cover key LAC territories*

Sep. 2025

GÅRDP launches Rfl to identify zoliflodacin commercial partner for Brazil

- SERIOUS BACTERIAL INFECTIONS
- SCIENTIFIC AFFAIRS AND REVIVE
- NEONATAL SEPSIS
- SEXUALLY TRANSMITTED INFECTIONS

ACCESS

ORGANIZATION

PAHO: Pan American Health Organization
CR: Carbapenem-resistant
HC: Hospital das Clínicas
Unifesp: Federal University of São Paulo


UFRJ: Federal University of Rio de Janeiro
Cemetron: Tropical Medicine Centre of Rondônia

Fiocruz: Oswaldo Cruz Foundation
Aries: Antimicrobial Resistance Institute of São Paulo
BSAC: British Society for Antimicrobial Chemotherapy
ACC: Antimicrobial Chemotherapy Conference
VPPCB: Vice Presidency of Research and Biological
Collections

LabSUR: Laboratory of Applied Bacteriology to Unique Health and Antimicrobial Resistance **Rfl:** Request for Information

LAC: Latin America and the Caribbean

* Brazil, Guatemala, Mexico and Panama



Partner spotlight: PAHO

The Pan American Health Organization (PAHO) is the world's oldest international public health agency. It is the specialized health agency for the Americas and also serves as the Regional Office of WHO for the Americas. PAHO and GARDP have been working together since 2021 and signed an agreement in September 2024, with the aim of improving regional antibiotic R&D, manufacturing and access in the context of the emergence and spread of antibiotic-resistant infections.

